Literature DB >> 33724344

Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory B cells in systemic sclerosis patients.

João R Lima-Júnior1,2, Lucas C M Arruda3, Maynara S Gonçalves2,4, Juliana B E Dias5, Daniela A Moraes5, Dimas T Covas4, Belinda P Simões4, Maria Carolina Oliveira4,5, Kelen C R Malmegrim4,6.   

Abstract

OBJECTIVES: The rationale of autologous haematopoietic stem cell transplantation (AHSCT) for autoimmune diseases is that high-dose immunosuppression eradicates autoreactive T and B cells and the infused autologous haematopoietic stem cells promote reconstitution of a naïve and self-tolerant immune system. The aim of this study was to evaluate the reconstitution of different B cell subsets, both quantitatively and functionally, in SSc patients treated with AHSCT.
METHODS: Peripheral blood was harvested from 22 SSc patients before transplantation and at 30, 60, 120, 180 and 360 days post-AHSCT. Immunophenotyping of B cell subsets, B cell cytokine production, signalling pathways and suppressive capacity of regulatory B cells (Bregs) were assessed by flow cytometry.
RESULTS: Naïve B cell frequencies increased from 60 to 360 days post-AHSCT compared with pre-transplantation. Conversely, memory B cell frequencies decreased during the same period. Plasma cell frequencies transiently decreased at 60 days post-AHSCT. IL-10-producing Bregs CD19+CD24hiCD38hi and CD19+CD24hiCD27+ frequencies increased at 180 days. Moreover, the phosphorylation of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase increased in B cells reconstituted post-AHSCT. Notably, CD19+CD24hiCD38hi Bregs recovered their ability to suppress production of Th1 cytokines by CD4+ T cells at 360 days post-AHSCT. Finally, IL-6 and TGF-β1-producing B cells decreased following AHSCT.
CONCLUSION: Taken together, these results suggest improvements in immunoregulatory and anti-fibrotic mechanisms after AHSCT for SSc, which may contribute to re-establishment of self-tolerance and clinical remission.
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  autologous haematopoietic stem cell transplantation; immune reconstitution; regulatory B cells; systemic sclerosis

Mesh:

Substances:

Year:  2021        PMID: 33724344     DOI: 10.1093/rheumatology/keab257

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  5 in total

Review 1.  Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Authors:  Tobias Alexander; Raffaella Greco
Journal:  Bone Marrow Transplant       Date:  2022-05-16       Impact factor: 5.174

Review 2.  The Role of B Cells in Scleroderma Lung Disease Pathogenesis.

Authors:  Stamatis-Nick C Liossis; Chrysanthi Staveri
Journal:  Front Med (Lausanne)       Date:  2022-07-04

Review 3.  Autologous Haematopoietic Stem Cell Transplantation and Systemic Sclerosis: Focus on Interstitial Lung Disease.

Authors:  Gianluca Bagnato; Antonio Giovanni Versace; Daniela La Rosa; Alberta De Gaetano; Egidio Imbalzano; Marianna Chiappalone; Carmelo Ioppolo; William Neal Roberts; Alessandra Bitto; Natasha Irrera; Alessandro Allegra; Giovanni Pioggia; Sebastiano Gangemi
Journal:  Cells       Date:  2022-03-01       Impact factor: 6.600

Review 4.  Role of B-Cell in the Pathogenesis of Systemic Sclerosis.

Authors:  Benjamin Thoreau; Benjamin Chaigne; Luc Mouthon
Journal:  Front Immunol       Date:  2022-07-12       Impact factor: 8.786

Review 5.  Reconstitution of the immune system and clinical correlates after stem cell transplantation for systemic sclerosis.

Authors:  Marianna Y Kawashima-Vasconcelos; Maynara Santana-Gonçalves; Djúlio C Zanin-Silva; Kelen C R Malmegrim; Maria Carolina Oliveira
Journal:  Front Immunol       Date:  2022-08-11       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.